Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research. 

A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about 20% of their body weight, whereas those on semaglutide lost about 14% over a 72-week period. 

"That translates to about a difference of eight pounds on average between the two drugs," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, said on "CBS Mornings" Monday.